IB
Ichosia Biotechnology
ichosia.com
Website unreachable since Oct 19, 2026
The startup develops derived red blood cells by genetically engineering human stem cells, enabling on-demand blood supply for patients at risk. This technology addresses the critical shortage of available blood products for healthcare providers and patients in need.
- Biotechnology
Updated 21 months ago
Funding
Raised to date
$240KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops derived red blood cells by genetically engineering human stem cells, enabling on-demand blood supply for patients at risk. This technology addresses the critical shortage of available blood products for healthcare providers and patients in need.